PT-141 Research Peptide

Peptora Research Peptide Library

PT-141 Research Peptide Overview

PT-141 Research Peptide, also known as bremelanotide, is a synthetic cyclic melanocortin analogue studied for its activity within the central melanocortin receptor system. Research has focused particularly on melanocortin receptors involved in neural signalling, including MC3R and MC4R, and on how these pathways influence physiological and behavioural responses.

Explore Research Materials What Are Research Peptides? Commonly Studied Peptides Testing & COAs

Peptide overview

What Is the PT-141 Research Peptide?

PT-141 is the research-development name associated with bremelanotide, a synthetic cyclic peptide belonging to the melanocortin-receptor agonist class.

Unlike many peptides in metabolic research that act primarily through incretin, growth-hormone or IGF-related pathways, PT-141 is associated with the melanocortin receptor system. This system includes five known melanocortin receptor subtypes, designated MC1R through MC5R.

PT-141 Research Peptide at a Glance

Alternative name: bremelanotide.

Research class: synthetic cyclic melanocortin peptide analogue.

Peptide structure: cyclic heptapeptide.

Research system: melanocortin receptors.

Important neural receptors: MC3R and MC4R.

Research areas: central melanocortin signalling, neural pathways, physiological responses and sexual-function research.

Peptide development

PT-141 Research Peptide and Melanocortin Biology

The melanocortin system consists of peptide ligands and five G-protein-coupled melanocortin receptors. Naturally occurring melanocortin peptides include alpha-melanocyte-stimulating hormone and related peptides derived from the proopiomelanocortin system.

PT-141 emerged from research involving synthetic melanocortin analogues. Early melanocortin studies demonstrated that modifying naturally occurring peptide sequences could create analogues with altered stability, potency and receptor activity.

α-MSH Research

Alpha-melanocyte-stimulating hormone is part of the endogenous melanocortin signalling system.

Melanocortin Receptors

Five melanocortin receptor subtypes, MC1R through MC5R, have been identified.

PT-141 Development

PT-141 was developed as a synthetic cyclic melanocortin analogue for receptor and physiological research.

CNS

Central Signalling

MC3R and MC4R are expressed predominantly within the central nervous system and are important in neural melanocortin research.

Molecular structure

PT-141 as a Cyclic Melanocortin Peptide

Published clinical literature describes PT-141 as a cyclic heptapeptide melanocortin analogue. The cyclic architecture distinguishes it from many linear research peptides.

Cyclization is an important peptide-engineering strategy because constraining peptide conformation can alter receptor interactions and susceptibility to enzymatic degradation.

Melanocortin Research Endogenous peptide system

→

Peptide Engineering Sequence modification

→

Cyclic Analogue Conformational constraint

→

PT-141 Bremelanotide

Research distinction: PT-141/bremelanotide is a specifically engineered melanocortin analogue. Findings involving it should not automatically be transferred to every melanocortin peptide or receptor agonist.

Receptor pharmacology

MC3R and MC4R in PT-141 Research

Melanocortin receptor subtypes have different tissue distributions and physiological roles. MC3R and MC4R are particularly relevant to central nervous system research.

Early human research described bremelanotide as an agonist at MC3R and MC4R. Later pharmacological and clinical literature has emphasized MC4R as particularly important to the compound's studied central effects.

MC3R

MC3R is a neural melanocortin receptor involved in central signalling and energy-homeostasis research.

MC4R

MC4R is widely studied within central melanocortin signalling and has been emphasized in bremelanotide research.

Central Nervous System

Neural melanocortin receptors provide a different research framework from peptides acting primarily through peripheral vascular mechanisms.

GPCR Signalling

Melanocortin receptors belong to the G-protein-coupled receptor family and initiate intracellular signalling following receptor activation.

Central pathways

PT-141 Research Peptide and Neural Signalling

One reason PT-141 attracted scientific attention was evidence that melanocortin receptor activation could influence physiological responses through central neural pathways.

This distinguishes melanocortin research from mechanisms centered primarily on local vascular signalling. Experimental literature has investigated regions of the central nervous system, including hypothalamic pathways, as potential components of melanocortin-mediated responses.

Central Signalling Is a Key Research Concept

PT-141 research helped demonstrate that physiological responses can be influenced by melanocortin receptor signalling within the central nervous system.

This does not mean every observed effect can be assigned to a single receptor or brain region. Melanocortin signalling involves multiple receptor subtypes and interconnected neural circuits.

Early human research

Early Clinical Research With PT-141

Early clinical studies evaluated PT-141 in both healthy participants and selected research populations.

A 2004 double-blind placebo-controlled study investigated intranasal PT-141 in healthy men and men with mild-to-moderate erectile dysfunction. A separate study evaluated subcutaneous PT-141 in healthy men and participants reporting an inadequate response to sildenafil.

These studies contributed to understanding the compound's pharmacokinetic profile and provided evidence that melanocortin receptor signalling could influence sexual-response physiology through mechanisms distinct from phosphodiesterase-5 inhibition.

Early Human Research

PT-141 and Melanocortin Receptor Research

Early PT-141 trials investigated pharmacokinetics, tolerability and physiological responses under controlled study conditions.

Flushing and nausea were among the commonly reported adverse events in the early clinical program.

These historical studies should be interpreted according to their specific populations, formulations, protocols and research endpoints.

Female research

PT-141 Research in Premenopausal Women

Clinical development later included studies involving premenopausal women with defined sexual-function disorders.

An early randomized double-blind study investigated subjective and physiological responses following bremelanotide exposure in premenopausal women with sexual arousal disorder.

A larger randomized placebo-controlled dose-finding trial subsequently evaluated bremelanotide in premenopausal women with female sexual dysfunction. These studies contributed to the later phase 3 development program.

Population matters: findings from trials involving specifically defined premenopausal female populations should remain tied to those populations and diagnostic criteria rather than generalized to all individuals.

Phase 3 evidence

PT-141 and the RECONNECT Clinical Trials

Two similarly designed phase 3 randomized, double-blind, placebo-controlled trials, known as the RECONNECT studies, evaluated bremelanotide in premenopausal women with acquired, generalized hypoactive sexual desire disorder.

Phase 3 — RECONNECT

Bremelanotide Clinical Research

The two studies randomized 1,267 women, with 1,247 included in the reported safety population and 1,202 in the modified intention-to-treat efficacy population.

Compared with placebo, the bremelanotide groups showed statistically significant improvements in the trials' sexual-desire and distress-related co-primary endpoints.

Nausea, flushing and headache were among the adverse events reported more frequently with bremelanotide than placebo.

These phase 3 findings concern a defined pharmaceutical intervention evaluated under controlled clinical-trial conditions. They do not establish the equivalence, safety or clinical suitability of independently supplied research material.

Regulatory distinction

PT-141 Research Peptide vs FDA-Approved Bremelanotide

This is one of the most important distinctions for interpreting PT-141 information.

Bremelanotide became an FDA-approved prescription pharmaceutical in the United States in 2019 for a specific indication involving premenopausal women with acquired, generalized hypoactive sexual desire disorder. That approval concerns the regulated pharmaceutical product evaluated through its clinical-development program.

Feature	Published / Approved Bremelanotide Drug	Laboratory Research Material
Molecule discussed	Bremelanotide	Material labelled PT-141/bremelanotide
Regulatory context	FDA-approved pharmaceutical for a defined U.S. indication	Non-clinical laboratory research material
Clinical evidence	Specific manufactured pharmaceutical studied in controlled trials	Cannot inherit pharmaceutical clinical evidence automatically
Intended context	Prescription medicine under its approved labelling	Controlled non-clinical laboratory research only

Critical distinction: the existence of an FDA-approved bremelanotide pharmaceutical does not make an independently supplied PT-141 research material an approved drug, establish pharmaceutical equivalence or authorize human use.

Safety research

Safety Findings in Bremelanotide Clinical Research

The broader bremelanotide clinical-development program included thousands of research participants across phase 1 through phase 3 studies.

An integrated safety analysis reported nausea as the most common adverse event. Flushing, headache and injection-site reactions were also reported more frequently than with placebo in the integrated double-blind phase 3 population.

Clinical research also documented small transient increases in blood pressure following exposure. These findings are part of the pharmaceutical clinical literature and are relevant when accurately describing the compound's research history.

Nausea

Nausea was the most commonly reported adverse event in the integrated clinical-development analysis.

Flushing

Flushing occurred more frequently in bremelanotide groups than placebo groups.

Headache

Headache was another commonly reported treatment-emergent adverse event.

Blood Pressure

Controlled studies identified small transient increases in blood pressure following bremelanotide exposure.

Evidence interpretation

How to Evaluate PT-141 Research Peptide Evidence

PT-141 has an unusually extensive human clinical-development history compared with many materials discussed in the research-peptide market. That makes precise interpretation especially important.

✓ Recognize PT-141 and bremelanotide as names associated with the same compound.

✓ Distinguish research material from an approved pharmaceutical product.

✓ Identify the receptor system being studied.

✓ Keep MC3R and MC4R findings in their experimental context.

✓ Identify the population included in each clinical study.

✓ Separate early exploratory research from phase 3 evidence.

✓ Keep safety findings tied to the pharmaceutical clinical program.

✓ Do not convert clinical literature into research-material use instructions.

Research comparison

PT-141 Research Peptide vs Metabolic Research Peptides

PT-141 differs substantially from several other compounds in Peptora's research library because its principal research framework is the central melanocortin system rather than incretin, amylin or mitochondrial signalling.

Research Compound	Primary Research System	Research Distinction
PT-141	Melanocortin receptors	Central melanocortin signalling, particularly MC3R/MC4R research
Cagrilintide	Amylin receptors	Long-acting amylin analogue
Tirzepatide	GIPR + GLP-1R	Dual incretin-receptor agonist
Retatrutide	GIPR + GLP-1R + GCGR	Triple-receptor agonist
MOTS-C	Mitochondrial/cellular signalling research	Mitochondrial-derived peptide research

See the Cagrilintide Research Peptide Overview, Tirzepatide Research Peptide Overview, Retatrutide Research Peptide Overview and MOTS-C Research Peptide Overview for comparison.

Analytical quality

Testing a PT-141 Research Peptide Batch

Published clinical evidence describes the pharmaceutical materials manufactured and controlled for those studies. It does not establish the identity, purity or measured content of an unrelated research batch.

Research materials therefore require batch-specific analytical documentation.

✓ Match documentation to the exact batch identifier.

✓ Confirm the stated molecular identity.

✓ Review chromatographic purity where reported.

✓ Review measured peptide content where reported.

✓ Confirm which analytical methods were used.

✓ Separate identity from purity and measured content.

✓ Review additional testing only where documented.

✓ Do not transfer results from another batch.

See Peptora's Testing & COAs, Testing Standards and Peptide Purity & Certificates of Analysis Explained.

Research network

Continue Exploring PT-141 Research Peptide Topics

PT-141 expands the Peptora research library into melanocortin receptor biology, adding a distinctly different signalling system to the metabolic, mitochondrial, GHRH, IGF and tissue-biology research covered throughout the library.

PT-141 and Related Peptide Research Resources

Use Peptora's broader educational network to compare peptide structure, receptor systems, evidence quality and analytical documentation.

What Are Research Peptides? → Commonly Studied Research Peptides → Cagrilintide Research Peptide Overview → IGF-1 LR3 Research Peptide Overview → Understanding Peptide Stability → Peptide Purity & COAs Explained → Testing & COAs → Complete Research Library →

PT-141 FAQ

PT-141 Research Peptide: Frequently Asked Questions

Common research questions about PT-141, bremelanotide, melanocortin receptors and published clinical research.

What is the PT-141 research peptide?

PT-141 is the research-development name associated with bremelanotide, a synthetic cyclic melanocortin peptide analogue studied for its activity at melanocortin receptors and within central neural signalling pathways.

Is PT-141 the same as bremelanotide?

PT-141 is the development name associated with bremelanotide. Published scientific literature commonly uses PT-141 in earlier studies and bremelanotide in later clinical development.

What type of peptide is PT-141?

Published research describes PT-141 as a synthetic cyclic heptapeptide melanocortin analogue.

Which receptors are studied with PT-141?

Research has particularly examined melanocortin receptors MC3R and MC4R. Later clinical literature has emphasized MC4R as an important receptor in bremelanotide's central pharmacology.

Does PT-141 act through the same pathway as tirzepatide?

No. PT-141 belongs to the melanocortin-receptor agonist class, whereas tirzepatide acts through GIP and GLP-1 receptors.

Has bremelanotide been studied in humans?

Yes. Bremelanotide underwent a substantial clinical-development program including early pharmacology studies, dose-ranging research and two phase 3 RECONNECT trials in a defined population of premenopausal women.

Does FDA approval of bremelanotide make research PT-141 an approved drug?

No. FDA approval applies to the regulated pharmaceutical product for its specific approved indication. It does not establish pharmaceutical equivalence, approval or human-use suitability for independently supplied laboratory research material.

How should a PT-141 research batch be evaluated?

Researchers should review batch-specific documentation for molecular identity, purity, measured content and any additional testing actually reported. Results from an approved pharmaceutical or another research batch cannot establish the analytical characteristics of an unrelated material.

Research use only

PT-141 Research Peptide for Controlled Laboratory Research

This page provides educational information about PT-141/bremelanotide, melanocortin receptors and published laboratory and clinical research. Discussion of an FDA-approved bremelanotide pharmaceutical is included only to accurately describe the compound's scientific and regulatory history.

Peptora Peptide Labs research materials are intended solely for controlled non-clinical laboratory research. They are not intended for human or veterinary consumption, compounding or clinical use. Nothing on this page provides medical advice, dosing or administration guidance or represents that a Peptora research material diagnoses, treats, cures or prevents disease.